Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, Yang Y, Zhou T, Phogat S, Mascola JR, Kwong PD.

J Virol. 2010 Aug;84(16):8098-110. doi: 10.1128/JVI.00966-10. Epub 2010 Jun 10.

2.

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11483-8. doi: 10.1073/pnas.1004600107. Epub 2010 Jun 2.

3.

Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone GA, O'Dell S, Pancera M, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Mascola JR, Kwong PD.

J Virol. 2011 Mar;85(6):2524-35. doi: 10.1128/JVI.02335-10. Epub 2010 Dec 29.

4.

Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16.

Liu L, Wen M, Wang W, Wang S, Yang L, Liu Y, Qian M, Zhang L, Shao Y, Kimata JT, Zhou P.

J Virol. 2011 Sep;85(17):8467-76. doi: 10.1128/JVI.00520-11. Epub 2011 Jun 29.

5.

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z; NISC Comparative Sequencing Program, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR.

Nature. 2014 May 1;509(7498):55-62. doi: 10.1038/nature13036. Epub 2014 Mar 2.

6.

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.

McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD.

Nature. 2011 Nov 23;480(7377):336-43. doi: 10.1038/nature10696.

7.

Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD.

Nat Struct Mol Biol. 2013 Jul;20(7):804-13. doi: 10.1038/nsmb.2600. Epub 2013 May 26.

8.

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Doores KJ, Burton DR.

J Virol. 2010 Oct;84(20):10510-21. doi: 10.1128/JVI.00552-10. Epub 2010 Aug 4.

9.

Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region.

Ofek G, McKee K, Yang Y, Yang ZY, Skinner J, Guenaga FJ, Wyatt R, Zwick MB, Nabel GJ, Mascola JR, Kwong PD.

J Virol. 2010 Mar;84(6):2955-62. doi: 10.1128/JVI.02257-09. Epub 2009 Dec 30.

10.

Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, Nieva JL, Pai EF.

J Virol. 2010 May;84(9):4136-47. doi: 10.1128/JVI.02357-09. Epub 2010 Feb 10.

11.

Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.

Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD.

J Virol. 2014 Mar;88(5):2426-41. doi: 10.1128/JVI.02837-13. Epub 2013 Dec 11.

12.

Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.

Maeso R, Huarte N, Julien JP, Kunert R, Pai EF, Nieva JL.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):863-76. doi: 10.1089/AID.2010.0265. Epub 2011 Jan 15.

PMID:
21142698
13.

Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies.

Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, Yang Y, Zhang B, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Kwong PD, Mascola JR.

J Virol. 2011 May;85(9):4578-85. doi: 10.1128/JVI.02585-10. Epub 2011 Feb 16.

14.

Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.

Gavrilyuk J, Ban H, Uehara H, Sirk SJ, Saye-Francisco K, Cuevas A, Zablowsky E, Oza A, Seaman MS, Burton DR, Barbas CF 3rd.

J Virol. 2013 May;87(9):4985-93. doi: 10.1128/JVI.03146-12. Epub 2013 Feb 20.

15.

Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41.

Chen J, Frey G, Peng H, Rits-Volloch S, Garrity J, Seaman MS, Chen B.

J Virol. 2014 Jan;88(2):1249-58. doi: 10.1128/JVI.02664-13. Epub 2013 Nov 13.

16.

Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies.

Ringe R, Phogat S, Bhattacharya J.

Virology. 2012 Apr 25;426(1):34-41. doi: 10.1016/j.virol.2012.01.011. Epub 2012 Feb 6.

17.

Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.

Gustchina E, Li M, Louis JM, Anderson DE, Lloyd J, Frisch C, Bewley CA, Gustchina A, Wlodawer A, Clore GM.

PLoS Pathog. 2010 Nov 11;6(11):e1001182. doi: 10.1371/journal.ppat.1001182.

18.

Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.

Willis JR, Sapparapu G, Murrell S, Julien JP, Singh V, King HG, Xia Y, Pickens JA, LaBranche CC, Slaughter JC, Montefiori DC, Wilson IA, Meiler J, Crowe JE Jr.

J Clin Invest. 2015 Jun;125(6):2523-31. doi: 10.1172/JCI80693. Epub 2015 May 18.

19.

Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.

Clark KR, Walsh ST.

Protein Sci. 2009 Dec;18(12):2429-41. doi: 10.1002/pro.255.

20.

Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.

Rujas E, Gulzar N, Morante K, Tsumoto K, Scott JK, Nieva JL, Caaveiro JM.

J Virol. 2015 Dec;89(23):11975-89. doi: 10.1128/JVI.01793-15. Epub 2015 Sep 16.

Items per page

Supplemental Content

Write to the Help Desk